関連ニュース

SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% conv

Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Institutions have pushed Halozyme Therapeutics, Inc. (HALO) shares up 769% since March 2014.

Halozyme Therapeutics is evolving into a diversified, high-margin royalty platform, reducing reliance on single assets like DARZALEX SC. HALO delivered 48% YoY revenue growth in 2Q26, with royalty rev

Halozyme Therapeutics shares have appreciated over 80% since my initial coverage and investment in 2024. My previous articles outlined a bullish investment thesis and detailed expectations for HALO's